11.01
+1.11(+11.21%)
Currency In USD
| Previous Close | 9.9 |
| Open | 9.98 |
| Day High | 11.2 |
| Day Low | 9.74 |
| 52-Week High | 28.09 |
| 52-Week Low | 7.8 |
| Volume | 3.06M |
| Average Volume | 764,512 |
| Market Cap | 600.44M |
| PE | -6.51 |
| EPS | -1.69 |
| Moving Average 50 Days | 12.72 |
| Moving Average 200 Days | 16.64 |
| Change | 1.11 |
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
4 hours ago
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
GlobeNewswire Inc.
Jun 01, 2025 5:12 PM GMT
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast to
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 22, 2025 9:00 PM GMT
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome datasetBOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed